Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06750315

CRP /Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

This study aimed to assess the clinical utility of the NLR (neutrophil lymphocyte ratio) and CRP Albumin ratio in predicting activity of IBD Patients in assiut university

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Assiut University, Asyut, Egypt

Loading trial locations.

About this study

IBD definition term for two conditions (Crohn's disease and ulcerative colitis) is a chronic idiopathic inflammatory disease affecting the large intestine. It is characterized by relapsing mucosal inflammation. The aim of treatment is to induce and maintain disease remission. Assessing disease activity may help in optimizing the management of IBD patients.

The neutrophil-to-lymphocyte ratio (NLR) is a simple index that can be calculated from the results of ordinary blood tests; it is calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count . As the NLR can reflect the systemic status of inflammation or immune response.

The underlying mechanism that the NLR was a predictor of clinilcal relapse in UC patients with Mucosal healing remains poorly understood. Neutrophils induce cytotoxicity and inflammation in UC. A high NLR value may be due to high activity in UC and lowered mucosal barrier function, which may lead to the migration of neutrophils through the gut microbiota .

CRP is routinely used as a surrogate measure of intestinal inflammation and as a prognostic measure of nonresponse to medical therapy and colectomy in patients with IBD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients more than 18 years newly diagnosed as IBD

-

Exclusion criteria

  • Patients Not DM Not cardiac failure Not Liver failure No malignancy

Treatment and study plan

Primary outcomes

  1. C-reactive protein /albumin ratio and neutrophil lymphocyte ratio in predicting activity in Inflammatory Bowel Disease Patients

    Time frame: 1 years

    Neutrophil lymphocyte ratio and CRP/Albumin ratio in detecting activity in IBD Patients.

Study contacts

Contact information is provided by the study sponsor or research team.

Amira Mohamed Ali Ahmed

CONTACT

[email protected]

01090176978

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

CRP/ Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 27, 2024
Registry last updated
Dec 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.